Soligenix Inc./$SNGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Ticker
$SNGX
Sector
Primary listing
Employees
14
Headquarters
Website
Soligenix Inc. Metrics
BasicAdvanced
$3.6m
-
-$2.14
1.94
-
Price and volume
Market cap
$3.6m
Beta
1.94
52-week high
$6.23
52-week low
$0.32
Average daily volume
994k
Financial strength
Current ratio
2.392
Quick ratio
2.145
Long term debt to equity
4.613
Total debt to equity
6.767
Profitability
EBITDA (TTM)
-11.842
Effective tax rate (TTM)
4.37%
Management effectiveness
Return on assets (TTM)
-81.35%
Return on equity (TTM)
-235.50%
Valuation
Price to book
0.66
Price to tangible book (TTM)
0.66
Price to free cash flow (TTM)
-0.174
Free cash flow yield (TTM)
-573.86%
Free cash flow per share (TTM)
-1.98
Growth
Earnings per share change (TTM)
-57.11%
3-year earnings per share growth (CAGR)
-69.73%
10-year earnings per share growth (CAGR)
-44.13%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soligenix Inc. stock?
Soligenix Inc. (SNGX) has a market cap of $3.6M as of May 04, 2026.
What is the P/E ratio for Soligenix Inc. stock?
The price to earnings (P/E) ratio for Soligenix Inc. (SNGX) stock is 0 as of May 04, 2026.
Does Soligenix Inc. stock pay dividends?
No, Soligenix Inc. (SNGX) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Soligenix Inc. dividend payment date?
Soligenix Inc. (SNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Soligenix Inc.?
Soligenix Inc. (SNGX) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.